Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
The First Affiliated Hospital with Nanjing Medical University
Japanese Foundation for Cancer Research
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
First Affiliated Hospital of Zhejiang University
Gustave Roussy, Cancer Campus, Grand Paris
M.D. Anderson Cancer Center
Fudan University
The First Affiliated Hospital with Nanjing Medical University
University of California, Irvine
The First Affiliated Hospital of Bengbu Medical University
Fudan University
Fudan University
Japanese Foundation for Cancer Research
UNICANCER
Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University
Queen Mary University of London
MedSIR
Lebanese University
OHSU Knight Cancer Institute
Peter MacCallum Cancer Centre, Australia
University of California, Irvine
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Fudan University
University of Nebraska
Tongji Hospital
ARCAGY/ GINECO GROUP
M.D. Anderson Cancer Center
Spanish Breast Cancer Research Group
University of Alabama at Birmingham
Japan Breast Cancer Research Group
Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dana-Farber Cancer Institute
SCRI Development Innovations, LLC
Massachusetts General Hospital
Dana-Farber Cancer Institute
National Taiwan University Hospital
Brown University
Yale University
Assiut University
Translational Oncology Research International
Case Comprehensive Cancer Center
Centro Nacional de Investigaciones Oncologicas CARLOS III
Abramson Cancer Center at Penn Medicine
Central European Cooperative Oncology Group
Dana-Farber Cancer Institute
Swiss Cancer Institute